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RESEARCH ARTICLE
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Nitroreductase (NTR2) in Leishmania
Susan Wyllie1*, Adam J. Roberts1, Suzanne Norval1, Stephen Patterson1, Bernardo
J. Foth2¤, Matthew Berriman2, Kevin D. Read1, Alan H. Fairlamb1*
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Abstract
Drug discovery pipelines for the “neglected diseases” are now heavily populated with
nitroheterocyclic compounds. Recently, the bicyclic nitro-compounds (R)-PA-824, DNDI-
VL-2098 and delamanid have been identified as potential candidates for the treatment
of visceral leishmaniasis. Using a combination of quantitative proteomics and whole
genome sequencing of susceptible and drug-resistant parasites we identified a putative
NAD(P)H oxidase as the activating nitroreductase (NTR2). Whole genome sequencing
revealed that deletion of a single cytosine in the gene for NTR2 that is likely to result in
the expression of a non-functional truncated protein. Susceptibility of leishmania was
restored by reintroduction of the wild-type gene into the resistant line, which was accom-
panied by the ability to metabolise these compounds. Overexpression of NTR2 in wild-
type parasites rendered cells hyper-sensitive to bicyclic nitro-compounds, but only mar-
ginally to the monocyclic nitro-drugs, nifurtimox and fexinidazole sulfone, known to be
activated by a mitochondrial oxygen-insensitive nitroreductase (NTR1). Conversely, a
double knockout NTR2 null cell line was completely resistant to bicyclic nitro-compounds
and only marginally resistant to nifurtimox. Sensitivity was fully restored on expression
of NTR2 in the null background. Thus, NTR2 is necessary and sufficient for activation of
these bicyclic nitro-drugs. Recombinant NTR2 was capable of reducing bicyclic nitro-
compounds in the same rank order as drug sensitivity in vitro. These findings may aid the
future development of better, novel anti-leishmanial drugs. Moreover, the discovery of
anti-leishmanial nitro-drugs with independent modes of activation and independent mech-
anisms of resistance alleviates many of the concerns over the continued development of
these compound series.
Author Summary
Visceral leishmaniasis (kala-azar) is a serious vector borne disease afflicting people, partic-
ularly in parts of Asia, Africa and Latin America. There are approximately 400,000 new
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cases and an estimated 40,000 deaths each year, making it the second biggest parasitic
killer after malaria.We recently discovered that delamanid–an oral nitro-drug used for the
treatment of tuberculosis–shows promise for the treatment of leishmaniasis with potential
to provide a much needed alternative to the current unsatisfactory anti-leishmanial drugs.
Understanding how a drug works is important for selecting the most appropriate partner
drugs to be used to increase efficacy and decrease toxicity in patients, to minimise the risk
of drug resistance emerging and in designing second generation drugs. Using a combina-
tion of biochemical and genetic approaches we have discovered a novel nitroreductase
(NTR2) that is necessary and sufficient for the anti-leishmanial activity of delamanid and
related experimental drugs containing a nitro-group attached to two fused rings. This
enzyme is responsible for activating bicyclic nitro-compounds to form toxic products that
kill the parasite. In contrast, the previously identified nitroreductase (NTR1), which specif-
ically activates monocyclic drugs, is not involved in this process. This knowledge can be
applied to develop novel treatments for this disease.
Introduction
New, safer and more effective treatments are required for visceral leishmaniasis (VL), a disease
endemic in parts of Asia, Africa and South America. VL results from infection with the proto-
zoan parasites Leishmania donovani or L. infantum and is responsible for ~50,000 deaths per
annum, with the number of cases estimated between 200,000 and 400,000 [1]. In 95% of cases,
death can be prevented by timely and appropriate drug therapy [2]; however, current treatment
options are far from ideal [3]. At present, miltefosine and liposomal amphotericin B are consid-
ered the front-line therapies and, while both drugs are considerably more effective than previ-
ous treatment options, they have their limitations. The principal drawbacks of amphotericin B
include high treatment costs, the requirement of a cold chain for distribution and storage, an
intravenous route of administration and unresponsiveness in some Sudanese VL patients [4].
Problems associated with miltefosine, the only oral drug, are its teratogenicity and high poten-
tial to develop resistance [5]. Thus, there is a pressing need for better, safer efficacious drugs
that are fit-for-purpose in resource-poor settings.
In the search for more effective drugs for VL and other “neglected tropical diseases”,
researchers have reassessed the therapeutic value of nitroheterocyclic compounds. Previously
avoided in drug discovery programs due to potential mutagenicity and carcinogenicity issues, a
nitro-drug is now being successfully used as part of a combination therapy for human African
trypanosomiasis (HAT). Nifurtimox-eflornithine combination therapy (NECT) consists of
oral treatment with the nitrofuran nifurtimox alongside infusions of eflornithine and has
resulted in cure rates of around 97% for the Gambian form of the disease [6]. The 2-substituted
5-nitroimidazole fexinidazole is now in clinical trials for use in the treatment of both HAT and
VL [7] (www.dndi.org), and has shown potential for the treatment of Chagas disease [8]. In
addition, until recently DNDi had a nitroimidazole compound (DNDI-VL-2098) [9] and
nitroimidazole back-up compounds at an advanced stage of pre-clinical development for use
in the treatment of VL (www.dndi.org). Thus, nitroheterocyclic compounds look set to play an
important role in the future treatment of these diseases.
Given the new found prominence of nitroheterocyclic drugs, concerted efforts are now
beingmade to elucidate their mechanisms of action. The mode of action of nifurtimox in the
trypanosomatids involves reductive activation via a NADH-dependent, type I bacterial-like
nitroreductase (NTR, LinJ.05.0660) resulting in the generation of a cytotoxic, unsaturated
Bicyclic Nitro-drug Activation in Leishmania
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open-chain nitrile derivative [10]. NTR has also been implicated in the bio-activation of fexini-
dazole and its sulfonic metabolite, with overexpression of the leishmanial homolog in L. dono-
vani found to increase sensitivity to fexinidazole sulfone by 15-fold [7]. Indeed, modulation
of the NTR levels within the trypanosomatids has been shown to directly affect sensitivity to
several nitroheterocyclic compounds in vitro, with reduced enzyme activity leading to drug
resistance [11–13]. The potential for NTR-related cross-resistance brings into question the
rationale of developing furtherNTR-activated nitro-compounds for the treatment of the trypa-
nosomatid-related diseases. Therefore, it is crucial to determine if any new anti-trypanosoma-
tid nitroaromatics are bio-activated by the NTR at an early stage in development.
Recently, we established that the novel nitroimidazo-oxazine (R)-PA-824 and the nitroimi-
dazo-oxazole delamanid (Deltyba, OPC-67683) have potential as effective anti-leishmanial
drugs [14,15]. Delamanid is an approved drug for the treatment of multi-drug resistant tuber-
culosis and (R)-PA-824 is the opposite enantiomer of (S)-PA-824 (pretomanid) currently in
Phase II trials for tuberculosis. The mechanism of action of these bicyclic nitro-compounds
does not involve bio-activation via NTR [14,15]. The des-nitro forms of both compounds were
inactive against L. donovani, suggesting that the nitro-group plays a key role in the anti-leish-
manial activity of this compound series. This raises the possibility that bio-reduction of (R)-
PA-824 and delamanid may bemediated by an as yet unidentified nitroreductase within L.
donovani. Here, we describe the identification and characterisation of an FMN dependent
NADH oxidoreductase (NTR2) in L. donovani which is responsible for the bio-activation of
(R)-PA-824, delamanid and other bicyclic nitro-drugs including DNDI–VL-2098. The broad
implications of a novel mechanism for the activation of anti-leishmanial nitroheterocyclic
compounds are discussed.
Results
(R)-PA-824-resistant Leishmania
To investigate the NTR-independent mechanism of action of (R)-PA-824, leishmania parasites
were selected for resistance against this nitroimidazo-oxazine. Starting with a clonal line of
drug-susceptibleL. donovani, promastigotes (the insect stage of the life-cycle) were cultured in
the continuous presence of (R)-PA-824 for a total of 80 days. Starting at 300 nM (3 x EC50,
Table 1), three independent cultures were exposed to increasing concentrations of drug until
they were routinely growing in 10 μM (R)-PA-824 (Fig 1A). Following drug selection, resistant
parasites were cloned by limiting dilution. The susceptibility of each cloned cell line to (R)-PA-
824 was determined and compared to that of wild-type parasites (Fig 1B). All three cloned cell
lines were found to be completely refractory to (R)-PA-824 at concentrations up to and includ-
ing 100 μM. Resistance to (R)-PA-824 in clone RES III was found to be stable over 45 passages
in culture in the absence of drug. In addition, resistance to (R)-PA-824 was retained by RES III
in the intra-macrophage amastigote stage of the parasite (S1 Fig).
At this point clone RES III was chosen for in-depth study. Although RES III was completely
resistant to (R)-PA-824, this clone remained sensitive to drugs from other chemical classes:
miltefosine and amphotericin B were equally potent against resistant and parental wild type
cells with EC50 values of 6.1 ± 0.3 and 5.9 ± 0.5 μM for miltefosine and values of 320 ± 23 and
390 ± 32 nM for amphotericin B against WT and RES III, respectively. However, RES III pro-
mastigotes showed marked cross-resistance to a number of structurally-related bicyclic nitroi-
midazo-oxazine compounds, including delamanid (>3,200-fold) and the preclinical candidate
DNDI-VL-2098 (>1,600-fold). In contrast, RES III showed little or no sign of cross-resistance
to the monocyclic nitro-drugs, fexinidazole sulfone (1.1-fold) and nifurtimox (3.3-fold)
(Table 1). Structures of the compounds tested are shown in Fig 2.
Bicyclic Nitro-drug Activation in Leishmania
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Proteomic analysis of (R)-PA-824 resistant promastigotes
Bio-activation of nifurtimox and fexinidazole sulfone is catalysed by an oxygen-insensitive
nitroreductase (NTR) in both T. brucei [10] and Leishmania [7] and loss of, or mutations in,
this enzyme has been shown to play a key role in drug resistance mechanisms in the trypanoso-
matids [16]. Therefore, we hypothesised that should an alternative nitroreductase be involved
in the bio-activation of (R)-PA-824 in Leishmania, changes in this enzymemay be evident in
parasites resistant to (R)-PA-824. Thus, a comparative proteomic analysis of drug-resistant
andWT promastigotes was conducted using stable isotope labelling by amino acids in cell cul-
ture (SILAC). WT parasites were grown in modified SDM-79 medium in the presence of nor-
mal L-arginine and L-lysine (R0K0) and mixed 1:1 with RES III cells grown for at least 6 cell
divisions in the presence of stable isotopes of L-arginine and L-lysine (R6K4) to achieve uni-
form labelling. Additionally, a label-swap experiment in which the ‘heavy’ and ‘light’ culture
Table 1. Sensitivity of WT, (R)-PA-824 resistant and transgenic L. donovani promastigotes to nitroheterocyclic compounds.
Nitroheterocyclic compounds EC50 values, nM (slope factor)a
Cell line (R)-PA-824 (S)-PA-824 Delamanid (S)-OPC 67683 DNDI-VL-2098 CGI-17341 Fexinidazole sulfone Nifurtimox
WT 93.6 ± 2.0
(3.5)
2567 ± 50
(3.5)
15.5 ± 0.1
(6.7)
146.9 ± 4.1
(2.9)
30.8 ± 2.8
(1.7)
30.6 ± 1.1
(10.7)
8,200 ± 101 (3.1) 1,800 ± 40
(3.2)
RES III >100,000 >50,000 >50,000 >50,000 >50,000 >20,000 8,900 ± 130 (3.1) 6,020 ± 32
(2.6)
NTR2OE 8.7 ± 0.3 (2.0) 95 ± 1.6 (2.2) 0.8 ± 0.03
(4.2)
48 ± 3.0 (2.7) 5.4 ± 0.38
(2.4)
1.9 ± 0.1 (8.9) 4600 ± 30 (2.7) 122 ± 8.2 (2.8)
NTR2DKO >100,000 >50,000 >50,000 N.D. >50,000 N.D. 7,880 ± 70 (3.2) 6,400 ± 70
(2.8)
a Data are the weighted means and weighted standard errors of 3 independent experiments. Each individual experiment is derived from a 10 point dilution
curve, where each individual sample is measured in triplicate.
N.D–not determined
doi:10.1371/journal.ppat.1005971.t001
Fig 1. (R)-PA-824 resistance in vitro. (A) Schematic representation of the generation of a (R)-PA-824 resistant cell line
in Leishmania donovani. Each passage of cells in culture (black circles) is indicated. (B) Dose-response curves for WT
(black circles) and RES III resistant cells (red circles). The curves are the non-linear regression fits using a two-parameter
EC50 equation, yielding EC50 values of 262 ± 14 nM and > 100 μM for (R)-PA-824 against WT and RES III cells,
respectively. Data are the mean ± standard deviation of triplicate cultures in a single experiment.
doi:10.1371/journal.ppat.1005971.g001
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media were reversed was also carried out. Cell cultures of WT and RES III were harvested by
centrifugation and cell pellets extractedwith detergent. Extracted lysates were then pooled,
fractionated by SDS-PAGE, digested with trypsin and analyzed by LC-MS/MS. Individual pep-
tides with a heavy to light ratio of 1.0 indicate an equal abundance in both populations.
In the combined proteomic dataset, 2119 proteins were identified by at least one uniquely
mapped peptide, prior to filtering the datasets and combining the label-swap experiments. This
resulted in the identification of 1472 proteins with a quantifiable expression change between
the parental and the RES III cell line. Statistical significancewas assessed using significanceB,
leading to the identification of 38 proteins with significantly altered expression levels compared
to the wild type (S1 Table). The most striking change was of a hypothetical NADH:FMN-
dependent oxidoreductase (Uniprot: E9AGH7; GeneDB: LinJ.12.0730) identified to be
~16-fold less abundant in RES III parasites (Fig 3A).
Role of a putative FMN-dependent NADH oxidase in the bio-activation
of (R)-PA-824
To determine if this putative FMN-dependent NADH oxidoreductase had any role in the bio-
activation of (R)-PA-824, the open reading frame for LinJ.12.0730 was transfected into WT L.
donovani promastigotes. Overexpression of the enzyme was verified by western blotting (S2
Fig). Parasites overexpressing the enzyme were ~40-fold (EC50 = 3.5 nM) more susceptible to
(R)-PA-824 thanWT promastigotes (EC50 = 140 nM) (Fig 3B). To further verify the role of
this hypothetical oxidoreductase in bio-activation, the enzyme was overexpressed in our drug-
resistant cell line RES III (Fig 3C). Overexpressing the oxidoreductase in RES III promastigotes
Fig 2. Chemical structures of the bicyclic and monocyclic compounds used in this study. Procedures
for the synthesis of DNDI-VL-2098 and CGI-17341 are described in S1 Text.
doi:10.1371/journal.ppat.1005971.g002
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fully restored sensitivity to (R)-PA-824 (EC50 = 1.0 nM). These data provide compelling evi-
dence that the hypothetical FMN-dependentNADH oxidoreductase, identified in our SILAC
studies, is involved in the bio-activation of (R)-PA-824 in L. donovani. Henceforth, this enzyme
is known as NTR2 and the previously identified type I oxygen-insensitive nitroreductase as
NTR1 (LinJ.05.0660).
Genomic analysis of NTR2 in (R)-PA-824-resistant parasites
In an attempt to understand the mechanisms involved in the depletion of NTR2 from our drug
resistant cell lines and also to identify additional factors that may be involved in resistance, the
Fig 3. The role of NTR2 in resistance to (R)-PA-824 in Leishmania. (A) Plot of the proteomics data from (R)-PA-824
resistant clone RES III. Each protein identification is represented by a point plotted as the Log2 of their heavy-to-light
isotope ratio (x axis) versus the Log10 value of the intensities of the peptides belonging to each protein (y axis). Proteins
plotted in light blue were determined to have significantly different expression levels compared to those in WT parasites,
with the most significantly changed protein shown in red (LinJ.12.0730; NADH:flavin oxidoreductase/NADH oxidase,
putative). The identity of the proteins found to be consistently over- or under-expressed are listed in S1 Table. (B) Dose-
response curve of WT promastigotes (black circles) and promastigotes overexpressing NTR2 (red circles) to (R)-PA-824.
EC50 values of 140 ± 4.6 and 3.5 ± 0.2 nM were determined for WT and NTR2-overexpressing parasites, respectively.
Overexpression of NTR2 was confirmed by western blotting (S2 Fig). (C) The susceptibility of RES III parasites (red
circles) and RES III parasites overexpressing NTR2 to (R)-PA-824 (black circles). RES III parasites were insensitive to
(R)-PA-824 at concentrations up to and including 100 μM while these promastigotes overexpressing NTR2 returned an
EC50 value of 1 ± 0.02 nM. Data are the mean ± SD of triplicate cultures. (D) Representation of the frame shift and
premature termination of NTR2 translation that results from deletion of a cytosine at genomic position 483544 in (R)-PA-
824-resistant clones. The frame shift results in a shortened open reading frame and corresponding amino acid sequence
(highlighted in bold), with red indicating the frame-shifted part of this sequence.
doi:10.1371/journal.ppat.1005971.g003
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complete genomes of each independently derived resistant clone (RES I, II and III) were
sequenced. Surprisingly, first-pass analysis revealed only 12 single nucleotide polymorphisms
(SNPs) resulting in nonsynonymous changes in 3 ORFs in the drug-resistant clones (S2 Table).
At this point in our studies, SILAC analysis focused our attention on the role of NTR2 in nitro-
heterocyclic drug activation and resistance. Complementing this finding, closer examination of
NTR2 and its flanking sequences identified the deletion of a single cytosine (genomic position
483544 on chromosome 12 in LdBPK; C457 in the open reading frame) withinNTR2 that
results in a frame shift and premature termination of NTR2 translation (Fig 3D). Despite the
fact that each clone appeared to be genetically distinct (S2 Table), this deletion was identified
in both allelic copies of NTR2 in all 3 independently generated resistant clones. The reason for
this unusual finding is not clear. Nonetheless, these data, alongside our failure to detect full
length NTR2 in RES III parasites (S2 Fig), confirm that each (R)-PA-824-resistant clone is
effectively NTR2 null and further strengthen our hypothesis that NTR2 is principally responsi-
ble for (R)-PA-824 bio-activation. A comprehensive analysis of the sequencing data from our
(R)-PA-824-resistant parasites will be reported in a subsequent publication.
Can NTR2 activate other nitroheterocyclic drugs?
Having established its role in the bio-activation of (R)-PA-284, we assessed the possible role of
NTR2 in the activation of other Leishmania-active nitroheterocyclic compounds (Table 1). The
potencies of these compounds were determined against WT promastigotes andWT transgenic
parasites overexpressing NTR2, where hypersensitivity in transgenic parasites is indicative of a
compound activated via NTR2. As expected, the (S)-enantiomer of PA-824, an anti-tubercular
clinical candidate [17], was 27-fold more potent against parasites with elevated levels of NTR2
thanWT. Structurally-related compounds including delamanid, CGI-17341 and DNDI-VL-
2098 are also activated by NTR2. NTR2-overexpressing parasites showed a<2-fold increase in
susceptibility to fexinidazole sulfone suggesting that this nitroimidazole, previously shown to be
activated by NTR1, is unlikely to be an efficient substrate for NTR2. However, another known
substrate of NTR1, nifurtimox,was 15-fold more potent against NTR2 overexpressing parasites
suggesting that this compoundmay be a substrate of both enzymes in L. donovani.
Metabolism of (R)-PA-824 and DNDI-VL-2098 in L. donovani
Levels of (R)-PA-824 metabolism inWT and NTR2-overexpressing parasites were monitored
by UPLC-MS/MS in cultures of promastigotes treated with 160 nM of drug over a 24-h period.
(R)-PA-824 was essentially stable in culture medium alone with a t1/2 of>24 h (Fig 4A). The
addition of L. donovani promastigotes to culture medium resulted in a marked increase in the
rate of disappearance of the drug (t1/2 = 14 h) associated with the appearance of several drug
metabolites. Metabolism was further increased in cultures of parasites overexpressing NTR2
(t1/2 = 0.5 h), such that drug levels had dropped below the limit of quantification (0.31 nM) by
4 h. Similar rates of drugmetabolismwere also observed in cultures incubated with both 15
nM delamanid (EC50 value, Fig 4B) and 20 nMDNDI-VL-2098 (10 x EC50 value Fig 4C). How-
ever, the instability of these compounds in medium alone was higher than those seen with (R)-
PA-824. This instability can be explained by the fact that delamanid is known to be primarily
metabolised in plasma by albumin [18]. Likewise,DNDI-VL-2098 is reportedly unstable in
plasma [9], presumably for the same reason.
Enzymatic analysis of recombinant NTR2
To further study the substrate specificity of NTR2, the recombinant enzyme was expressed and
purified to homogeneity in three chromatographic steps to obtain a yield of 15 mg l−1 of a yellow
Bicyclic Nitro-drug Activation in Leishmania
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Fig 4. Metabolism of nitroheterocyclics in cultures of WT and NTR2-overexpressing promastigotes.
Metabolism of 160 nM (R)-PA-824 (A), 15 nM delamanid (B) and 20 nM DNDI-VL-2098 (C) in media alone
(black circles), wild type L. donovani promastigotes (blue circles) and NTR2-overexpressing L. donovani
promastigotes (red circles). The half-life of (R)-PA-824 in media alone, in cultures of WT promastigotes and
cultures of promastigotes overexpressing NTR2 were >24 h, 14 h and 0.5 h, respectively. DNDI-VL-2098
incubated in media alone had a half-life of 3.1 h and half-lives of 0.83 h and 0.13 h in cultures of WT and
Bicyclic Nitro-drug Activation in Leishmania
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product (Fig 5A), indicative of a flavoprotein. Using an established spectrophotometricmethod,
FMNwas confirmed as the bound co-factor in NTR2 [19]. Analysis of the recombinant protein
by size-exclusion chromatography revealed that NTR2 elutes primarily as a monomer at *40
kDa (Fig 5B), close to the predictedmolecularmass of 39.6 kDa (Fig 5B). This was confirmedby
MS to be 39.4 kDa for the recombinant protein by MALDI–TOF analysis.
Our preliminary studies indicate that this enzyme was able to utilise NADH or NADPH as
a reductant. The ability of NTR2 to reduce a variety of nitroheterocyclic compounds was then
assessed in the presence of 100 μMNADPH (Fig 5C). The highest rates of activity were
observedwith the bicyclic nitro-compounds structurally related to (R)-PA-824. Further, the
highest rates of NTR2 metabolism broadly correlate with the most potent anti-leishmanial
NTR2-overexpressing parasites, respectively. The half-life of delamanid was 12 h in media alone and 1.6 h in
WT promastigotes. As the disappearance of delamanid in NTR2-overexpressing parasites was plotted to a
double exponential decay, two half-lives were calculated as 0.096 h for k1 and 0.64 h for k2.
doi:10.1371/journal.ppat.1005971.g004
Fig 5. Characterisation of LdNTR2. (A) Purification of recombinant LdNTR2 from E. coli BL21(DE3)pLysS [pET15b-LdNTR2].
Lane 1, insoluble fraction; lane 2, soluble fraction; lane 3, pooled fractions from Ni2+-affinity chromatography; lane 4, soluble protein
following removal of histidine tag; and lane 5, pooled fractions from size-exclusion chromatography. MALDI analysis confirmed that
the minor bands represent NTR2 degradation products. (B) Gel filtration profile of the LdNTR2. The inset shows a plot of elution
volume against the log molecular mass (MW) of a standard protein mixture (black circles). The red circle represents the elution
volume of NTR2. (C) Metabolism of nitroheterocyclic compounds by recombinant NTR2. Initial rates of metabolism were measured
in assays containing 100 μM nitro-compound, 100 μM NADPH and 500 nM NTR2. Rates of metabolism with NADPH and NADH
alone were 0.0124 ± 0.001 and 0.0084 ± 0.0006 μmol min-1 mg-1, respectively. Rates represent the mean ± SD of triplicate
measurements. (D) Immunoblots of whole cell extracts (equivalent of 5×106 parasites in each lane) from L. donovani mid-log
promastigotes (L), metacyclic promastigotes (M) and axenic amastigotes (A) were probed with LdNTR2-specific polyclonal
antiserum. Known amounts of purified recombinant LdNTR2 were loaded as standards for the quantification of the cellular levels of
NTR2.
doi:10.1371/journal.ppat.1005971.g005
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compounds, DNDI-VL-2098 (15.7 ± 0.4 μmol min-1 mg-1) and delamanid (7.2 ± 0.7 μmol
min-1 mg-1). In keeping with our overexpression studies in Table 1, recombinant NTR2 was
able to reduce nifurtimox, albeit at a comparatively low rate (0.30 ± 0.02 μmol min-1 mg-1) but
showed little activity with fexinidazole sulfone (0.004 ± 0.0002 μmol min-1 mg-1).
Quantitation of cellular NTR2 levels
Using a NTR2-specific polyclonal antiserum generated against our purified recombinant pro-
tein, we were able to confirm that NTR2 is expressed in all developmental stages of the Leish-
mania parasite by probing an immunoblot of whole cell lysates (Fig 5D). Single bands of
approximately 40 kDa, close to the predictedmolecularmass of NTR2 (39.6 kDa), were
detected in cell lysates of log phase promastigotes (the dividing insect stage), metacyclic pro-
mastigotes (the insect stage infective to mammals) and axenic amastigotes (the intracellular
mammalian stage). The cellular concentration of NTR2 in each of these parasite stages was
determined by densitometry. NTR2 levels in each developmental stage were found to be
remarkably similar with concentrations of 1.70 μM, 1.73 μM and 1.75 μM in promastigotes,
metacyclics and amastigotes, respectively.
Cellular localisation of NTR2
Immunofluorescence studies confirm that L. donovani NTR2 localises to the cytosol of mid-
log promastigotes (Fig 6). Staining of promastigotes with an anti-NTR2 polyclonal antibody
showed extensive and even staining throughout the cells, except for the nucleus and kineto-
plast, demonstrating the cytosolic location of this enzyme (Fig 6C and 6D).
Assessing the essentiality of NTR2
The studies described above show that loss of NTR2 is strongly associatedwith resistance to (R)-
PA-824. However, this does not exclude the possibility that additional genes may also be
involved. To address this issue, we investigated the impact of NTR2 loss by gene deletion in a
WT genetic background. Thus,NTR2 null parasites were generated by classical gene replacement.
Fig 6. Cellular localisation of NTR2. Phase contrast images of L. donovani promastigotes (A),
promastigotes stained with DAPI (4,6-diamidino-2-phenylindole) (B), immunofluorescence staining of
promastigotes with NTR2 anti-serum (FITC) (C) and a merged FITC and DAPI image (D). The kinetoplastid
(K) and nucleus (N) are indicated in the DAPI stained image.
doi:10.1371/journal.ppat.1005971.g006
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Both copies of theNTR2 gene were sequentially replaced with hygromycin and puromycin drug
resistance genes. Southern blot analysis of genomic DNA from putative double knockout (DKO)
cells confirmed that they wereNTR2 null (Fig 7A). Loss of both copies ofNTR2 had no obvious
effects on the viability of these parasites with DKO promastigotes growing at the same rate in cul-
ture as WT and achieving similar cell densities. DKO parasites were found to be completely
refractory to (R)-PA-824 at concentrations up to and including 100 μM (Fig 7C), as found in our
resistant lines obtained by drug selection. Similar results were found for (S)-PA-824, delamanid
Fig 7. Modulation of NTR2 levels and its effect on (R)-PA-824 potency, compound metabolism and
infectivity. (A) (i) Schematic representation of the stepwise generation of the NTR2 DKO cell line in L. donovani.
One allele of NTR2 was replaced with the puromycin resistance gene (PAC) by homologous recombination; the
remaining allele was replaced with a hygromycin resistance gene (HYG) by homologous recombination resulting
in a NTR2 null cell line. (ii) Southern-blot analysis of XhoI-digested genomic DNA (*5 μg) from wild-type L.
donovani (LdBOB) cells (lane 1), NTR2-double knockout clone 1 (DKO1) cells (lane 2) and NTR2-double
knockout clone 2 (DKO2) cells (lane 3). The NTR2 ORF probe shows allelic LdNTR2 at 10 kb. (B) EC50 values
were determined for (R)-PA-824 against WT (black), DKO1 (red), DKO2 parasites (blue) and DKO1 parasites
with an NTR2 add-back (green). An EC50 value of 115 ± 3 nM was determined for (R)-PA-824 against WT
parasites, DKO1 and DKO2 were unaffected by the drug at concentrations up to and including 10 μM, while an
EC50 value of 5.5 ± 0.03 nM was determined for DKO1 parasites expressing an NTR2 add-back. (C) Metabolism
of 160 nM (R)-PA-824 in media alone (black circles), wild type L. donovani promastigotes (blue circles), DKO
parasites (red circles) and DKO parasites plus NTR2 add-back (green circles). The half-life of (R)-PA-824
metabolism in cultures of WT parasites is 12.5 h, while the half-life of DKO parasites with an NTR2 add-back is
0.5 h. (D) Mean numbers of WT, DKO (clone 1) and RES (clone RES III) amastigotes infecting mouse peritoneal
macrophages. Grey bars, invasion after 24 h; black bars, replication after 72h. Differences in the replication of
WT versus RES and DKO amastigotes in macrophages were confirmed as highly significant (P values equal to
0.0057 and 0.0087, respectively) using an un-paired student t-test (**).
doi:10.1371/journal.ppat.1005971.g007
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and DNDI-VL-2098 (Table 1). Susceptibility to fexinidazole sulfone remained unchanged and
susceptibility to nifurtimox decreasedmarginally in good agreement with RES III. Adding back
an exogenous copy of NTR2 to DKO null parasites entirely recovered sensitivity to (R)-PA-824
demonstrating that NTR2 is necessary and sufficient for activation of toxicity with compounds
such as (R)-PA-824, delamanid or DNDI-VL-2098.
The impact of NTR2 deletion on drugmetabolismwas determined by measuring the con-
centration of (R)-PA-824 in cultures of WT and DKO over a 24-h period. Samples of culture
were removed at defined intervals and the supernatants analysed by UPLC-MS/MS, as previ-
ously described (Fig 7B). WT parasites metabolised (R)-PA-824 at a similar rate to that seen in
our earlier study (t1/2 = 12.5 h). In contrast, rates of metabolism in medium alone and in cul-
tures of DKO promastigotes were negligible over the same 24-h period. The addition of an
NTR2 add-back to DKO parasites recovered the ability of these cells to metabolise (R)-PA-824
(t1/2 = 0.5 h). These data confirm that NTR2 alone is necessary and sufficient for metabolic
conversion of bicyclic nitro-drugs.
Loss of functionalNTR2 did not have a material effect on the ability of DKO or RESmetacyc-
lic promastigotes to infect peritonealmacrophages, as determined by comparing the mean num-
bers of amastigotes per infectedmacrophage to that seen inWT-infected macrophage cultures
24h following infection (Fig 7D). However, there did appear to be a moderate but statistically
significant effect on the ability of NTR2-deficient parasites to replicate within peritonealmacro-
phages with mean numbers of amastigotes per infectedmacrophage considerably lower in DKO
and RES cultures at 72h. The reduced ability of NTR2 null amastigotes to replicate within mac-
rophages was entirely alleviated by the addition of an NTR2-addback. Collectively, these data
suggest that, while NTR2 is not essential for L. donovani survival, null parasites do appear to suf-
fer a moderate but statistically significant loss of “fitness” in macrophage infections that may
have implications for the propagation of NTR2-related drug resistance in the field.
Discussion
Drug discovery pipelines for the “neglected diseases” are now heavily populated with nitrohe-
terocyclic compounds. Following the success of nifurtimox as part of NECT [6] and the re-
discovery of fexinidazole [7,8,20], researchers have been quick to recognise and exploit the
therapeutic potential of these compound classes. However, the development of multiple com-
pounds with a likely shared mode of action for any disease indication is not without significant
risk. An over-emphasis on one compound class can leave drug pipelines vulnerable to multiple
compound failures associated with a single resistance mechanism. Specifically, it is well estab-
lished that parasites resistant to one nitro-drug are often cross-resistant to a second [13];
for example nifurtimox-resistantT. brucei are cross-resistant to fexinidazole and vice versa
[11,16]. Here, cross-resistance has been largely explained by a common, nitroreductase-related
mechanism of drug activation [13,21]. This has made researchers wary of developing further
nitro-compounds for the treatment of the trypanosomatid diseases. In this study we have con-
firmed that several bicyclic nitro-drugs, either in preclinical development or demonstrating
promising anti-leishmanial activity, are not activated via NTR1, known to activate monocyclic
nitro-compounds nifurtimox, benznidazole and fexinidazole [7,10,12,22]. Importantly, resis-
tance to bicyclic nitro-compounds in Leishmania promastigotes does not result in striking lev-
els of cross-resistance to NTR1-activated compounds. The discovery of anti-leishmanial nitro-
drugs with independentmodes of activation and independent mechanisms of resistance
alleviates many of the concerns over the continued development of these compound series.
It is worth emphasizing the power of using orthogonal approaches such as pharmacology
combined with genomics and proteomics to elucidate mechanisms of drug action. Several lines
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of evidence presented here establish that the primary enzyme target for metabolic activation of
bicyclic nitro-compounds in Leishmania is NTR2, an NAD(P)H-dependent flavoprotein. First,
whole genome sequencing and SILAC proteomic analysis confirmed that Leishmania promas-
tigotes, resistant to (R)-PA-824 and cross-resistant to a number of bicyclic nitro-drugs, are
effectively NTR2 null. Second, re-introduction of NTR2 into (R)-PA-824-resistant parasites
restored drug susceptibility while overexpression of NTR2 resulted in hypersensitivity to bicy-
clic nitro-drugs. Third, and perhaps the most compelling evidence that NTR2 is primarily
responsible for metabolic activation of these compounds, is the complete abrogation of suscep-
tibility in NTR2 null parasites.
Increasedmetabolism of (R)-PA-824, delamanid and DNDI-VL-2098 in promastigotes
overexpressing NTR2 and the absence of metabolism in NTR2 DKO cultures suggests that
NTR2 catalyses metabolic conversion of these compounds. InMycobacterium tuberculosis
metabolism of (S)-PA-824 is catalyzed by an unusual deazaflavin-dependent nitroreductase
(Ddn) [23–25], an enzyme which is absent in Leishmania spp. Incubation of (S)-PA-824 with
recombinantM. tuberculosis Ddn leads to the formation of three primarymetabolites, the
most abundant being (S)-des-nitro-PA-824 [25,26]. Des-nitro-formation in this bacterium
leads to the concomitant release of reactive nitrogen species, including nitric oxide. Transcrip-
tional profiling suggests that respiratory poisoning by nitric oxide is likely to be central to the
anti-mycobacterial action of (S)-PA-824 under hypoxic conditions [27]. Further studies will be
required to elucidate the chemical identity of the metabolite(s) resulting fromNTR2 bio-activa-
tion of bicyclic nitro-drugs and their role(s) in parasite killing.
The endogenous function of NTR2 in Leishmania remains to be determined. BLAST
searches of NTR2 revealed high similarity to prokaryotic alkene reductases for the “old yellow
enzyme” family. Members of this “ene”-reductases family catalyze a diverse range of reactions,
usually on substrates with an α/β unsaturated carbonyl group [28–30]. The closest orthologue
of NTR2 in Trypanosoma cruzi is the enzyme prostaglandin F2α synthase, also known as old
yellow enzyme, which shares 44% identity with L. donovani NTR2. This NAD(P)H-dependent
oxidoreductase has been implicated in both the mechanisms of action of, and resistance to,
benznidazole and nifurtimox in the American trypanosome [31]. There is no enzyme equiva-
lent to NTR2 in the genome of T. brucei, perhaps explaining the conspicuous lack of potency of
bicyclic nitro-drugs against these parasites [15].
Our future studies will involve a comprehensive kinetic and structural characterisation of
NTR2 and an elucidation of the active drugmetabolites responsible for cell death. Understand-
ing the binding mode of compounds in the active site of NTR2 may facilitate the design of
improved bicyclic nitro-drugs for the treatment of VL.
Materials and Methods
Ethics statement
All animal experiments were approved by the Ethical ReviewCommittee at the University of
Dundee and performed under the Animals (Scientific Procedures) Act 1986 (UKHome Office
Project Licence PPL 70/8274) in accordance with the European Communities Council Direc-
tive (86/609/EEC).
Cell lines and culture conditions
The clonal Leishmania donovani cell line LdBOB (derived fromMHOM/SD/62/1S-CL2D,
originally isolated from a patient in the Sudan in 1962) [32] was grown as promastigotes at
26°C in modifiedM199 media supplemented with FCS certified free frommycoplasma (6).
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Test compounds
(R)-PA-824 and (S)-PA-824 were synthesized in-house following published procedures [7,15].
Fexinidazole sulfone was prepared either by oxidation of fexinidazole [33], or by modification
of a published method [34]. DNDI-VL-2098 was prepared by adapting the reported syntheses
of related compounds [35]. Methods for the synthesis of delamanid and (S)-OPC-67683 are
described in detail in our recent publication [14]. CGI-17341 was prepared using a modifica-
tion of a previous method [36]. The purity of all synthesized compounds was determined by
liquid chromatography-mass spectrometry and found to be>95%.Where appropriate, the
optical rotation of chiral compounds was checked against literature values and in all cases was
found to be in good agreement. Full experimental details and analytical data for the synthesis
of DNDI-VL-2098 and CGI-17341 are reported in S1 Text.
In vitro drug sensitivity assays
Drug sensitivity assays were carried out in triplicate promastigote cultures exactly as previously
described [15]. Data were fitted by non-linear regression to a two-parameter EC50 equation
using GraFit version 5.0.13.
Generation of drug-resistant parasites
(R)-PA-824 resistant lines were generated by sub-culturing a freshly cloned line of wild-typeL.
donovani in the continuous presence of this compound. Starting at a sub-lethal concentration
of 300 nM (R)-PA-824, the drug concentrations in 3 independent cultures were increased in a
step-wisemanner, usually by 2-fold. After a total of 80 days in culture, when promastigotes
were able to survive and grow in 10 μM (R)-PA-824, the resulting cell lines were cloned by lim-
iting dilution in the absence of (R)-PA-824. One clone (RES III) was selected for further biolog-
ical studies.
SILAC labelling, cell culture and sample preparation
SILAC SDM-79 medium (SDM-79SILAC) was prepared as previously described [37]. Briefly,
SDM-79SILAC was supplemented with either normal isotopic abundance L-Arginine and
L-Lysine (SDM-79SILAC-L), or with L-arginine.HCl [U-13C6] and L-lysine.2HCl [4,4,5,5-D4]
(SDM-79SILAC-H, CK Gas Products, UK) at the same concentration as described in the original
SDM-79 formulation [38].
For SILAC labelling of cultures, LdBOBWT or (R)-PA-824 resistant promastigotes, in the
log phase of growth, were washed 3 times with phosphate-buffered saline, and resuspended at
1 × 104 cells ml-1 in either SDM-79SILAC-L or SDM-79SILAC-H. Cells were passaged every 2 days
and grown for a total of 10 days under labelling conditions. Cells (5×107) were harvested by
centrifugation (10 min, 4°C, 1600 g) and washed twice in PBS prior to being resuspended in
Laemmli buffer (Bio-Rad Laboratories) and heated at 95°C for 10 min. The equivalent of 5×106
cells of each cell sample (WT and (R)-PA-824 resistant promastigotes) were pooled together
and then subjected to electrophoresis on a 4–12%NuPAGE SDS/PAGE gel. When the sample
had entered approximately 2 cm into the gel, electrophoresis was stopped and the gel stained
with Instant Blue (expedeon). Sample lanes were excised and subjected to in-gel digestion for
18 h at 37°C with 12.5 μg ml-1 Trypsin Gold (Promega) in 10 mMNH4HCO3 and 10% acetoni-
trile. Tryptic peptides were recovered in 45% acetonitrile, 1% formic acid and lyophilized prior
to analysis.
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Mass spectrometry data acquisition and processing—SILAC
Liquid chromatography tandemmass spectrometrywas performed by the Proteomic Facility
at the University of Dundee. Tryptic peptides were separated on a fully automated Ultimate
U3000 Nano RSL Cnano system (Thermo Scientific) fitted with a 0.1 × 2 cm PepMap C18 trap
column and a 75 μm × 50 cm reverse phase PepMap C18 nanocolumn (Thermo Scientific).
Samples were loaded in 0.1% formic acid (buffer A) and separated using a binary gradient con-
sisting of buffer A and buffer B (80% acetonitrile, 0.08% formic acid). Peptides were eluted
with a linear gradient from 2 to 40% buffer B over 124 min. The HPLC system was coupled to
an LTQ Orbitrap Velos Pro mass spectrometer (Thermo Scientific) equipped with a Proxeon
nanospray ion source. The mass spectrometer was operated in data dependent mode to per-
form a survey scan over a range 335–1800 m/z in the Orbitrap analyzer (R = 60,000), with each
MS scan triggering ten MS2 acquisitions of the ten most intense ions. The Orbitrap mass ana-
lyzer was internally calibrated on the fly using the lock mass of polydimethylcyclosiloxane at
m/z 445.120025.
Data was processed usingMaxQuant version 1.5.0 which incorporates the Andromeda
search engine [39,40]. Proteins were identified by searching a protein sequence database con-
taining L. infantum annotated proteins (downloaded from UniProt, http://www.uniprot.org/
proteomes/UP000008153) supplemented with frequently observed contaminants (porcine
trypsin, bovine serum albumin and human keratins). Initial MS tolerance was set as 4.5 ppm
with the MS/MS tolerance set at 0.5 Da. Cysteine carbamidomethylation was set as a fixed
modificationwith protein N-acetylation and methionine oxidation as variable modifications.
Peptides were required to be a minimum of 7 amino acids in length with only the uniquely
mapped peptides used in the calculation of SILAC ratios. The minimumH/L ratio count was
set to be 1 and peptide and protein false discovery rates of 0.01 were calculated by searching a
database of reversed sequences. The SILAC ratios of proteins identified in both label swap
experiments were averaged, whereas reportedH/L ratios identified only in one experiment
were included if the H/L percentage variability was<100% [41]. Differential expression was
assessed using a significanceB test built into Perseus v.1.5.0 with a Benjamini–Hochberg FDR
threshold of 0.01 [40].
Generation of overexpression constructs
The primers used to generate constructs for genetic manipulation and protein expression (S3
Table) were designed using the L. infantum genome sequence (tritrypdb.org). Primers were
designed against a putative NADH:flavin oxidoreductase/NADH oxidase (LinJ.12.0730). The
accuracy of all assembled constructs was verified by sequencing.
LdNTR2 overexpression vectors were generated by amplifying the gene from genomic
DNA using the LdNTR2-BamHI sense and antisense primers for cloning into pIR1-SAT and
LdNTR2-SmaI sense and LdNTR2-XbaI antisense for cloning into pX63-3HA. PCR products
were then cloned into the pCR-Blunt II-TOPO vector (Invitrogen) and sequenced. The
pCR-Blunt II-TOPO-gene constructs were then digested with appropriate restrictions enzymes
and the fragments cloned into either the pIR1SAT or pX63-3HA expression vectors.
Assembly of knockout constructs
NTR2 gene replacement cassettes were generated by amplifying a region of DNA encompassing
the 5´-untranslated region (UTR), open reading frame (ORF) and 3´-UTR of LdBOBNTR2
from genomic DNA with primers 5´UTR-NotI_s and 3´UTR-NotI_as, using Pfu polymerase.
This sequence was then used as a template for the amplification of the individual regions used
in the assembly of replacement cassettes containing the selectable drug resistance genes
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puromycin N-acetyl transferase (PAC) and hygromycin phosphotransferase (HYG), exactly as
previously described [42].
Generation of LdBOB transgenic cell lines
Mid-log-phase L. donovani promastigotes (LdBOB)were transfected with overexpression con-
structs using the Human T-Cell Nucleofector kit and the Amaxa Nucleofector electroporator
(program V-033). Following transfection, cells were allowed to grow for 16–24 h in modified
M199 medium [32] with 10% fetal calf serumprior to appropriate drug selection (100 μg
nourseothricin μg ml−1, hygromycin 50 μg ml-1, puromycin 20 μg ml-1 and 100 μg G418 ml−1).
Cloned cell lines were generated by limiting dilution, maintained in selectivemedium, and
removed from drug selection for one passage prior to experiments.
Infectivity assays
In-macrophage infectivity assays were carried out using starch-elicited mouse peritoneal
macrophages harvested from BALB/c mice [7] and metacyclic promastigotes, as previously
described [12].
Metabolism of (R)-PA-824, delamanid and DNDI-VL-2098 in L.
donovani promastigotes
Metabolism studies were performed at 160 nM (R)-PA-824, 15 nM delamanid and 20 nM
DNDI-VL-2098 in culture medium alone and in the presence of either wild type, NTR2 null or
NTR2 overexpressing L. donovani promastigotes (1 x 107 parasites ml-1). At 0, 0.5, 1, 2, 4, 6, 8
and 24 h aliquots were removed, precipitated by addition of a 2-fold volume of acetonitrile and
centrifuged (1,665 x g, 10 min, RT). The supernatant was diluted with water to maintain a final
solvent concentration of 50% and stored at -20°C prior to UPLC-MS/MS analysis, as described
below. Data were processed using GraFit (version 7.0.2; Erithacus software) and fitted to a sin-
gle exponential decay (with the exception of delamanid incubated with NTR2OE parasites
which were fitted to a double exponential decay) and the half life (t1/2) was calculated from the
elimination rate constant (k):
t1=2 ¼
ln2
k
Metabolite identification—UPLC-MS/MS methods
UPLC-MS/MSwas performed on a Waters Acquity UPLC interfaced to a Waters Xevo TQ-S
MS (Waters, Manchester, UK). Chromatographic resolution was achieved on a 2.1 x 50 mm
Acquity BEH C18, 1.7 μm column which was maintained at 40°C with an injection volume of
8 μl. The mobile phase consisted of A: deionizedwater plus 0.01% (v/v) formic acid and B: ace-
tonitrile plus 0.01% (v/v) formic acid at a flow rate of 0.6 ml min-1. The initial gradient was 5%
B held for 0.5 min before increasing to 95% B from 0.5–2 min, where it was held from 2–2.6
min before decreasing back to 5% B from 2.6–3 min. Mass spectra were obtained using electro-
spray ionization (ESI), in positive ion mode with the following conditions: capillary 3.5 kV;
desolvation temperature 600°C; source temperature 150°C; desolvation gas flow (nitrogen)
1000 l h-1 and collision gas (argon) gas of 0.15 ml min-1. Multiple reactionmonitoring (MRM)
was performed using the transition 359.87> 174.96, cone voltage of 5 V and collision energy
of 26 V for (R)-PA-824, the transition 535.02> 351.08, cone voltage of 16 V and collision
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energy of 33 V for delamanid and 359.92> 230.92 at a cone voltage of 5 V and collision energy
of 12 V for VL-2098 Data was processed using the TargetLynx feature of Mass Lynx v4.1.
Cloning, expression and purification of recombinant NTR2
LdNTR2was amplified from genomic DNA using the primers LdNTR2-NdeI_s and LdNTR2-
BamHI_s (S3 Table). The resulting PCR product was then cloned into the pCR-Blunt II-TOPO
vector (Invitrogen) and sequenced. The pCR-Blunt II-TOPO-gene constructs were then
digested with appropriate restriction enzymes and the fragment cloned into the multiple clon-
ing site of the pET-15b-TEV expression vector. The resulting pET15b-NTR2 expression con-
struct was transformed into BL21 (DE3)pLysS competent cells and recombinant expression
was carried. Overnight starter cultures were used to inoculate one litre of LB media supple-
mented with 50 μg ml-1 ampicillin. These cultures were grown at 37°C with shaking (200 rpm)
until an OD600 of 0.7 was reached. At this point the temperature was dropped to 22°C, expres-
sion induced by the addition of 0.5 mM IPTG and cultures incubated for a further 12 h. Cells
were harvested by centrifugation (5090 g, 30 min at 4°C) and resuspended in buffer A (50 mM
Na+ phosphate, 150 mMNaCl, 25 mM imidazole pH adjusted to 7.5) supplemented with an
EDTA free protease inhibitor cocktail tablet (Roche), DNase I and lysozyme. Cells were dis-
rupted using a Constant Systems, continuous flow cell disruptor at 30 kpsi and soluble protein
recovered after centrifugation (40,000 × g, 30 min at 4°C). Soluble protein was loaded onto a
5-ml HisTrap column and eluted with an increasing gradient of imidazole (25–500 mM) in
buffer A. Fractions containing the protein of interest were pooled prior to the addition of TEV
protease and dialysed into 50 mMNa+ phosphate buffer containing 150 mMNaCl overnight at
4°C using a 10 kDaMWCO dialysis cassette. The protein was loaded onto the 5-ml HisTrap
column and then eluted with buffer A. Fractions containing the protein were loaded onto a
Superdex 75 26/60 column equilibrated in buffer B (50 mM tris containing 150 mMNaCl, pH
7.5) and separated. After analysis by SDS-PAGE, fractions containing NTR2 were pooled and
concentrated for storage in buffer B containing 10% glycerol and supplemented with 1 mM
DTT. Analytical size exclusion was carried out in buffer B on a Superdex 75, 10/300 column
injecting 100 μl of 2 mg ml-1 protein and comparing the elution volume to that of the BioRad
gel filtration standards. Final purity was assessed by SDS-PAGE, MALDI-TOF and tryptic
mass fingerprinting.
NTR2 enzymatic activity
NTR2 activity was measured by following the change in absorbance at 340 nm due to NADPH
oxidation. A reactionmixture (1 ml) containing 50 mMHEPES, pH 7.0 and 100 μMNADPH
was incubated at 25°C for 1 min. NTR2 was added to a final concentration of 500 nM and the
background rate of NADPH oxidation was measured for 1 min. The reaction was initiated by
the addition of 100 μM of nitroheterocyclic test compounds and initial rates of NADPH oxida-
tion in the presence of these compounds were measured. Enzyme activity was calculated using
ε = 6220 M−1 cm−1 and reported in μmol min-1 mg-1.
Quantitation of cellular levels of NTR2 in cell lysates
Mid-log promastigotes, metacyclic promastigotes and axenic amastigotes were harvested by
centrifugation (10 min, 4°C, 1600g) and washed twice in PBS. Cells (5×107) were resuspended
in 100 μl Laemmli buffer (Bio-Rad Laboratories) and heated at 95°C for 10 min. The equivalent
of 5×106 cells were separated by SDS-PAGE on a 4–12%NuPAGE gel, alongside known
amounts of purified recombinant NTR2 (4–32 ng). Cellular proteins were transferred on to
Protran nitrocellulosemembrane (Whatman) by electrotransfer. Membranes were probed with
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primary rabbit antisera generated against purified, recombinant NTR2 (1:3000 dilution, Davids
Biotechnologie, Regensburg, Germany) prior to probing with an HRP (horseradish peroxi-
dase)-conjugated goat anti-rabbit polyclonal secondary serum (1:5000; BioRad). The blot was
developed using ECL detection reagent kit (GE Healthcare) and exposed to Amersham Hyper-
film ECL (GEHealthcare). The developed filmwas scanned and the protein bands were quanti-
fied by densitometrywith ImageJ (NIH). Cell volumes, used to determine the intracellular
concentration of NTR2, were measured using a Schärfe Systems CASY cell counter yielding
2.86 ± 0.02, 2.5 ± 0.01 and 1.74 ± 0.04 μl (108 cells)-1 for LdBOBmid-log promastigotes,
metacyclic promastigotes and axenic amastigotes, respectively. Total protein in 2% SDS was
determined using the Pierce BCA Protein Assay Kit and found to be similar across all develop-
mental stages (0.82, 0.78 and 0.68 mg (108 cells)-1).for mid-log promastigotes, metacyclic pro-
mastigotes and axenic amastigotes, respectively).
Immunofluorescence studies
Mid-log L. donovani promastigotes were washed twice in PBS before being fixed in 2% (w/v)
paraformaldehyde in PBS (0.15 M NaCl, 5 mM potassium-phosphate buffer, pH 7.4). Fixed
parasites were then treated with Triton X-100 (0.1%) for 10 min, prior to the addition of 0.1M
glycine for an additional 10 min. Parasites were then washed with PBS and air-dried onto poly-
lysine coated microscope slides. Slides were then blocked by incubation in 50% (v/v) foetal calf
serum (FCS), PBS for 10 min prior to incubation in L. donovani NTR2 antiserum diluted 1:50
in PBS containing 5% FCS for 1 h at room temperature. Following washing in PBS, slides were
incubated for a further 1 h in fluorescein isothiocyanate-conjugated goat anti-rabbit secondary
antibody diluted 1:200 in PBS. Slides were washed again in PBS before beingmounted using
the SlowFade Light Antifade Kit with 4,6-diamidino-2-phenylindole (DAPI; Molecular
Probes), as instructed by the manufacturers.
Whole genome sequencing and genomic variant analysis
Genomic DNA was prepared from L. donovani (R)-PA-824 resistant clones RES I, II and III
and the wild-type parental strain. For each sample, 1.5–2 μg of genomic DNA was used to pro-
duce amplification-free Illumina libraries of 400–600 base pairs (bp) length [43]. Sequencing
was carried out on an Illumina HiSeq 2000 sequencer according to the manufacturer’s standard
sequencing protocol and yielded 38.0–48.9 million reads of 100 bp length per library. The
resulting data sets represented a nominal sequencing coverage of the L. donovani genome (32.4
Mb) of 117.4- to 150.9-fold. The Illumina data were aligned against the L. donovani BPK282A1
reference genome [44] assembly using SMALT v0.7.4 (http://www.sanger.ac.uk/resources/
software/smalt/) employing an exhaustive search (-x) and with parameters wordlen = 13 (-k),
skipstep = 2 (-s), minscor = 0.60 (-m), and insertmax = 1000 (-i). Variants were called using
SAMtools v0.1.19 mpileup (-Q 15 for baseQ/BAQ filtering) and BCFtools [45]. The raw
sequence data are available under the study number PRJEB5833 and the following accession
numbers at the European Nucleotide Archive (http://www.ebi.ac.uk/ena): LdWT: ERS421640;
Ld PA824R-I: ERS421641; Ld PA824R-II: ERS421642; Ld PA824R-III: ERS421643.
Supporting Information
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the non-linear regression fits using a four-parameter EC50 equation, yielding EC50 values of
2.1 ± 0.15 μM and> 50 μM for (R)-PA-824 against WT and RES III cells, respectively.
(TIF)
S2 Fig. Levels of NTR2 inWT, RES III and NTR2 overexpressing promastigotes.WT (open
circles) and RES III (closed circles) metacyclic promastigotes were used to infect starch-elicited,
mouse peritoneal macrophages. Dose response curves are the non-linear regression fits using a
four-parameter EC50 equation, yielding EC50 values of 2.1 ± 0.15 μM and> 50 μM for (R)-PA-
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(TIF)
S1 Table. List of proteins found to be consistently over- or under-expressed in RES III com-
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